In a report published Thursday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $15.00 price target on BioCryst Pharmaceuticals BCRX.
In the report, MLV & Co noted, “BioCryst Pharmaceuticals (BCRX) reported significant progress in 2Q14 highlighted by positive results from OPuS-1 and a public offering that netted ~$107MM. Although interest for BCX4430, which has potential utility against Ebola virus disease (EVD), is increasing, we are focused on progress with BCRX's other pipeline assets as drivers of the stock. Specifically, as the OPuS-1 Ph 2a trial of BCX4161 for prophylactic treatment of HAE met all study objectives, BCRX is now poised for BCX4161's advancement into OPuS-2, a Ph 2b trial planned for YE14. We also believe the expected dilution (~19%) from raising capital in June removed an overhang on the stock, as we estimate BCRX's $133MM in cash adequate for a significant ramp in its clinical development activities in HAE beyond 2015. We believe the company's momentum going into 2H14 will be positively reflected in BCRX shares. Therefore, we maintain our BUY recommendation and $15 PT.”
BioCryst Pharmaceuticals closed on Wednesday at $13.03.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in